ArticleEuropean journal of nuclear medicine and molecular imaging2025
Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05535621 (68Ga-HER2 Affibody PET/CT Imaging for HER2-Positive Cancer Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
68Ga-HER2 Affibody PET/CT Imaging for HER2-Positive Cancer Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeRecently, novel human epidermal growth factor receptor 2 antibody-drug conjugate therapies have shown remarkable efficacy in treating urothelial carcinoma, highlighting the growing need for comprehensive assessment of HER2 expression in tumors to identify patients who could benefit. However, non-invasive methods for assessing HER2 status in patients with urothelial carcinoma remain limited. This study aimed to preliminarily evaluate the clinical potential of [68Ga]Ga-HER2 affibody PET/CT for non-invasive assessment of HER2 expression in patients with urothelial carcinoma. MATERIALS AND
methodsA cohort of 25 patients with urothelial carcinoma was retrospectively included from a prospective parent study (NCT05535621), and sequential PET/CT using [68Ga]Ga-HER2 affibody and [18 F] FDG was performed. HER2 status was assessed through pathological evaluation using immunohistochemistry, with scoring categories of 0, 1+, 2+, and 3+. Lesion uptake on PET/CT was quantified using the maximum standardized uptake value (SUVmax). Comparisons of SUVmax between primary tumor groups with different HER2 expression levels (HER2-positive IHC 2+, 3 + vs. HER2-negative IHC 0, 1+, and HER2-expression IHC 1+, 2+, 3 + vs. HER2-zero IHC 0) were conducted using nonparametric statistical tests. Additionally, the correlation between tumor SUVmax and HER2 expression status was analyzed, and the HER2 PET metastasis-positive rate at the patient level in metastatic urothelial carcinoma was determined.
resultsTwenty-five patients (mean age, 65.6 years ± 11.1 [SD]); 18 men) with urothelial carcinoma were enrolled. HER2 status in primary tumor was confirmed IHC 0 in four cases, IHC 1 + in three cases, IHC 2 + in six cases, IHC 3 + in three cases, and unknown in seven cases with potential HER2 expression. One patient with ureterostomy recurrence had HER2 IHC 1+, while another case was confirmed IHC 2 + through biopsy of metastatic lesion. In 16 participants with urothelial carcinoma, the SUVmax of HER2-positive primary tumors (IHC 2 + and 3+, n = 9) were higher than those of HER2-negative tumors (IHC 0 and 1+, n = 7) (median SUVmax, 7.07 ± 0.69 vs. 4.48 ± 1.14, p = 0.042) on [68Ga]Ga-HER2 affibody PET/CT. Additionally, a similar difference was observed between the HER2-expression group (IHC 1+, 2+, 3+, n = 12) and the HER2-zero group (IHC 0, n = 4) (median SUVmax, 6.97 ± 0.70 vs. 2.85 ± 0.19, p = 0.001). Primary tumors in 13 of the 16 patients were semi-quantitatively measurable on FDG PET/CT imaging, with no significant difference in FDG SUVmax between the HER2-positive and HER2-negative group (7 HER2-positive vs. 6 HER2-negative; median SUVmax: 19.56 ± 5.02 vs. 19.10 ± 3.13, p = 0.731). Spearman correlation analysis revealed a positive correlation between HER2 PET SUVmax and HER2 expression levels in primary urothelial carcinoma (R = 0.727, p = 0.001), whereas no correlation was found between FDG SUVmax and HER2 expression levels (p > 0.05). In 14 patients with metastatic urothelial carcinoma, HER2 affibody PET/CT identified HER2 PET-positive metastatic lesions with a 92.86% positivity rate (13/14).
conclusion[68Ga]Ga-HER2 affibody PET/CT is a valuable non-invasive method for evaluating HER2 expression in patients with urothelial carcinoma.
trial registrationNCT05535621. Registered 18 December 2021.
Indexed as
Identifiers
39951137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.